Page 4 - Final Slides
P. 4

Disclosure of commercial support







        • This program has received financial support from Merck


            in the form of an educational grant








        • Potential for conflict(s) of interest:


               • Merck markets Keytruda (pembrolizumab) which will be


                   discussed in this program



























                                                                                                                                                                                        5
   1   2   3   4   5   6   7   8   9